RxDoctor Payments DataLook up a doctor →

George Dakwar, MD

Urology · Media, PANPI 1366609448

Payments from drug & device makers

$60,145in general payments, 2019–2025

Across 539 payments — averaging $111.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$18K
  • Covidien LP$17K
  • Johnson & Johnson$9K
  • Bayer$3K
  • Pfizer$3K
  • Boston Scientific$2K
  • plus $8K from 38 others

What the payments were for

  • Consulting fees$41,44469%
  • Travel & lodging$4,9518%
  • Food & beverage$13,35822%
  • Education$3911%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,145 in reported general payments places this provider in the 90th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$568,861
Medicare patients
808
Services billed
21,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide261$3,048,361
ErleadaApalutamide163$2,173,594
OrgovyxRelugolix730$1,991,183
NubeqaDarolutamide54$711,302
Abiraterone Acetate83$162,381
MyrbetriqMirabegron51$44,126
GemtesaVibegron14$10,071
Tamsulosin Hcl474$7,308
Testosterone21$3,619
Alfuzosin Hcl ErAlfuzosin Hcl150$3,201
Potassium Citrate ErPotassium Citrate11$2,682
Silodosin28$2,381
Trospium Chloride28$1,406
Doxycycline Hyclate91$996
Finasteride68$833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,013$3,092,487312 claims
Johnson & JohnsonErleada$9,072$2,173,594163 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$296$2,001,254744 claims
BayerNubeqa$3,350$711,30254 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$665$162,38183 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 urology providers in Pennsylvania.

Other urology in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →